Legcolax powder for oral solution 10 g. sackets №4


Manufacturer: Ukraine

Symptomatic treatment of constipation.



Legcolax powder Storage
active substance: macrogol;

1 sachet contains polyethylene glycol (macrogol) 4000 in terms of 100% substance 4 g or 10 g

1 jar contains polyethylene glycol (macrogol) 4000 in terms of 100% substance 150 g or 300 g

Legcolax powder Dosage form
Powder for oral solution.

Main physical and chemical properties: white or almost white powder.

Legcolax powder Pharmacotherapeutic group
Laxatives. Osmotic laxatives. Macrogol. ATX code A06A D15.

Legcolax powder Pharmacological properties
Pharmacodynamics. Due to the formation of hydrogen bonds with water molecules, the drug retains it in the intestine. This increases the fluid content in the intestinal cavity, which improves the process of defecation.

Pharmacokinetics. The laxative effect of the drug occurs 24-48 hours after ingestion.

The drug is not absorbed or metabolized. Excreted unchanged.

Symptomatic treatment of constipation.

Hypersensitivity to macrogol.

Inflammatory diseases of the colon (nonspecific ulcerative colitis, Crohn’s disease, toxic megacolon).

Intestinal obstruction or suspected intestinal obstruction.

Perforation of the gastrointestinal tract or its threat.

Abdominal pain of unknown origin.

Interaction with other medicinal products and other forms of interaction
There may be a delay in the absorption of drugs taken concomitantly with Legcolax. Therefore, it is recommended to take the drug separately from other drugs, with an interval of at least 2 hours.

Features of application
Prior to treatment, the organic nature of constipation should be ruled out. Treatment of constipation with any drug is only an adjunct therapy provided a healthy lifestyle and diet, namely: consumption of more fluids and fiber, appropriate physical activity and recovery of intestinal function.

The maximum duration of use for children – no more than 3 months.

The fact that symptoms do not disappear even as a result of drug use and adherence to a proper diet may indicate other pathologies that need diagnosis and treatment.

Cases of aspiration with large volumes of polyethylene glycol electrolytes through a nasogastric tube have been reported. A special risk of aspiration is observed in children with neurological disorders of swallowing.

It should be used with caution in patients prone to water-electrolyte imbalance, namely: elderly patients, patients with impaired liver or kidney function; with concomitant use of diuretics, given the possibility of diarrhea. It is also recommended to monitor electrolyte balance.

The drug does not contain sugar, so it can be prescribed to patients with diabetes, as well as persons whose diet excludes galactose.

Because the drug contains macrogol, there may be symptoms of hypersensitivity to the active substance (see section “Adverse reactions”).

Use during pregnancy or breastfeeding.

The drug can be prescribed during pregnancy or breastfeeding.

Ability to influence the speed of reaction when driving a car or other machinery.

Not installed.


The drug can be used in children over 6 months of age.